Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) dropped 0% on Friday . The stock traded as low as $3.55 and last traded at $3.56, with a volume of 158,742 shares trading hands. The stock had previously closed at $3.56.

ARLZ has been the topic of several analyst reports. Chardan Capital reduced their target price on shares of Aralez Pharmaceuticals from $15.50 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 16th. Dundee Securities cut their price objective on shares of Aralez Pharmaceuticals from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 16th.

The firm has a 50 day moving average price of $3.65 and a 200-day moving average price of $4.73. The company’s market cap is $231.11 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Tuesday, May 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.48. The firm earned $8.10 million during the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals’s revenue was up 84.1% on a year-over-year basis. Equities analysts expect that Aralez Pharmaceuticals Inc. will post ($1.00) EPS for the current year.

In other news, insider Andrew I. Koven bought 71,500 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was acquired at an average price of $3.49 per share, for a total transaction of $249,535.00. Following the acquisition, the insider now owns 1,610,306 shares of the company’s stock, valued at $5,619,967.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Scott J. Charles bought 50,000 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were purchased at an average price of $3.49 per share, with a total value of $174,500.00. Following the acquisition, the chief financial officer now directly owns 213,368 shares in the company, valued at approximately $744,654.32. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.